HRP970006A2 - Azetidines - Google Patents

Azetidines

Info

Publication number
HRP970006A2
HRP970006A2 HR9600235.7A HRP970006A HRP970006A2 HR P970006 A2 HRP970006 A2 HR P970006A2 HR P970006 A HRP970006 A HR P970006A HR P970006 A2 HRP970006 A2 HR P970006A2
Authority
HR
Croatia
Prior art keywords
azetidines
Prior art date
Application number
HR9600235.7A
Other languages
English (en)
Inventor
Sandra Dora Meadows
Original Assignee
Sandra Dora Meadows
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandra Dora Meadows filed Critical Sandra Dora Meadows
Publication of HRP970006A2 publication Critical patent/HRP970006A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR9600235.7A 1996-01-05 1997-01-03 Azetidines HRP970006A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9600235.7A GB9600235D0 (en) 1996-01-05 1996-01-05 Therapeutic agents

Publications (1)

Publication Number Publication Date
HRP970006A2 true HRP970006A2 (en) 1998-06-30

Family

ID=10786682

Family Applications (1)

Application Number Title Priority Date Filing Date
HR9600235.7A HRP970006A2 (en) 1996-01-05 1997-01-03 Azetidines

Country Status (38)

Country Link
US (1) US6242438B1 (cs)
EP (1) EP0871623B1 (cs)
JP (2) JP3123611B2 (cs)
KR (1) KR100275402B1 (cs)
AP (1) AP709A (cs)
AR (2) AR005338A1 (cs)
AT (1) ATE232526T1 (cs)
AU (1) AU708282B2 (cs)
BG (1) BG102589A (cs)
BR (1) BR9612412A (cs)
CA (1) CA2237189C (cs)
CO (1) CO4750815A1 (cs)
CZ (1) CZ209398A3 (cs)
DE (1) DE69626220T2 (cs)
DK (1) DK0871623T3 (cs)
DZ (1) DZ2155A1 (cs)
ES (1) ES2190486T3 (cs)
GB (1) GB9600235D0 (cs)
HR (1) HRP970006A2 (cs)
HU (1) HUP9903590A3 (cs)
IL (2) IL145324A0 (cs)
IS (1) IS1876B (cs)
MA (1) MA26417A1 (cs)
NO (1) NO311838B1 (cs)
NZ (1) NZ324712A (cs)
OA (1) OA10863A (cs)
PE (1) PE29798A1 (cs)
PL (1) PL185723B1 (cs)
RU (1) RU2158264C2 (cs)
SI (1) SI0871623T1 (cs)
SK (1) SK89598A3 (cs)
TN (1) TNSN96174A1 (cs)
TR (1) TR199801268T2 (cs)
TW (1) TW472054B (cs)
UY (1) UY24429A1 (cs)
WO (1) WO1997025322A1 (cs)
YU (1) YU71496A (cs)
ZA (1) ZA9747B (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714129D0 (en) 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
WO1999019297A1 (en) * 1997-10-15 1999-04-22 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
AU734908B2 (en) 1997-12-04 2001-06-28 Sankyo Company Limited Acylated hetero-alicyclic derivatives
GB9821898D0 (en) * 1998-10-08 1998-12-02 Pfizer Ltd Heterocycles
DE60129562T2 (de) * 2000-06-12 2008-04-17 The University Of Rochester Methode zur Behandlung von Hitzewallungen durch Verwendung eines Tachykinin-Rezeptor-Antagonisten
US6642226B2 (en) * 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
GB0130261D0 (en) 2001-12-18 2002-02-06 Pfizer Ltd Lactams as tachykinin antagonists
BR0307406A (pt) * 2002-02-01 2004-12-28 Hoffmann La Roche Indóis substituìdos como agonistas alfa-1
US7674783B2 (en) * 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
DE60312042T2 (de) * 2002-12-23 2007-10-31 Janssen Pharmaceutica N.V. Substituierte 1-piperidin-4-yl-4-azetidin-3-yl-piperazinderivate und deren verwendung als neurokininantagonisten
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
JP2008504275A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション Ｎ−置換ピペリジンおよびその医薬としての使用
US20060009491A1 (en) * 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
BRPI0608847A2 (pt) 2005-03-08 2010-02-02 Janssen Pharmaceutica Nv derivados de diaza-espiro-[4,4]-nonano substituìdos e seu uso como antagonistas de neurocinina
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
RU2402546C2 (ru) * 2008-11-20 2010-10-27 Федеральное государственное учреждение "27 Научный центр Министерства Обороны Российской Федерации" Способ получения метил 4-[(3,4-дихлорфенил)ацетил]-3-[(1-пирролидинил)метил]-1-пиперазинкарбоксилата
AR074755A1 (es) * 2008-12-16 2011-02-09 Astrazeneca Ab Derivados cuaternarios de piperidina y sus usos
AR076381A1 (es) * 2009-04-22 2011-06-08 Janssen Pharmaceutica Nv Azetidinil diamidas como inhibidores de monoacilglicerol lipasa

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226998A (en) * 1974-09-26 1980-10-07 Ciba-Geigy Corporation 1-Benzothiepin-4-carboxamides
GB1600880A (en) * 1978-05-23 1981-10-21 Lilly Industries Ltd Pharmaceutical compositions comprising hydantoin derivatives
SU1032752A1 (ru) * 1981-08-14 1990-11-07 Институт биохимии АН ЛитССР Калиева соль 4-(пиперидиназо)-N-ацетилбензолсульфамида, обладающа противовоспалительной активностью
SE8904298D0 (sv) * 1989-12-21 1989-12-21 Astra Ab New compounds
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE69405862T2 (de) * 1993-05-06 1998-01-15 Merrell Pharma Inc Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten
GB9315808D0 (en) * 1993-07-30 1993-09-15 Merck Sharp & Dohme Therapeutic agents
WO1995019344A1 (en) * 1994-01-13 1995-07-20 Merck Sharp & Dohme Limited Gem-disubstituted azacyclic tachykinin antagonists
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2717804B1 (fr) 1994-03-25 1996-06-21 Sanofi Sa Sels de composés hétéroaromatiques azotés substitués, procédé pour leur préparation et compositions pharmaceutiques en contenant.
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
NZ325581A (en) 1995-12-20 2000-03-27 Hoechst Marion Roussel Inc Substituted 4-(1h-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
GB9601202D0 (en) * 1996-01-22 1996-03-20 Pfizer Ltd Piperidones
GB9812037D0 (en) * 1998-06-04 1998-07-29 Pfizer Ltd Piperidones
GB9821898D0 (en) * 1998-10-08 1998-12-02 Pfizer Ltd Heterocycles

Also Published As

Publication number Publication date
JP3254205B2 (ja) 2002-02-04
IL124309A0 (en) 1998-12-06
TR199801268T2 (xx) 1998-10-21
BG102589A (en) 1999-09-30
IS4760A (is) 1998-05-28
SK89598A3 (en) 2000-02-14
CZ209398A3 (cs) 1999-04-14
NZ324712A (en) 1999-05-28
MA26417A1 (fr) 2004-12-20
DE69626220T2 (de) 2003-08-28
US6242438B1 (en) 2001-06-05
UY24429A1 (es) 2001-08-27
NO982651D0 (no) 1998-06-09
AR005339A1 (es) 1999-04-28
PL327665A1 (en) 1998-12-21
AP9600901A0 (en) 1997-01-31
CO4750815A1 (es) 1999-03-31
IL124309A (en) 2002-11-10
DZ2155A1 (fr) 2002-10-26
JP2000344741A (ja) 2000-12-12
IS1876B (is) 2003-05-28
EP0871623B1 (en) 2003-02-12
JPH11501667A (ja) 1999-02-09
TW472054B (en) 2002-01-11
GB9600235D0 (en) 1996-03-06
SI0871623T1 (en) 2003-08-31
PL185723B1 (pl) 2003-07-31
ZA9747B (en) 1998-09-30
KR19990077027A (ko) 1999-10-25
ES2190486T3 (es) 2003-08-01
NO311838B1 (no) 2002-02-04
AU1195097A (en) 1997-08-01
EP0871623A1 (en) 1998-10-21
AP709A (en) 1998-12-22
HUP9903590A2 (hu) 2000-05-28
PE29798A1 (es) 1998-06-11
ATE232526T1 (de) 2003-02-15
WO1997025322A1 (en) 1997-07-17
AU708282B2 (en) 1999-07-29
TNSN96174A1 (fr) 2005-03-15
AR005338A1 (es) 1999-04-28
JP3123611B2 (ja) 2001-01-15
DK0871623T3 (da) 2003-03-31
NO982651L (no) 1998-06-09
KR100275402B1 (ko) 2000-12-15
HUP9903590A3 (en) 2002-01-28
YU71496A (en) 1999-11-22
OA10863A (en) 2001-09-27
DE69626220D1 (de) 2003-03-20
RU2158264C2 (ru) 2000-10-27
IL145324A0 (en) 2002-06-30
BR9612412A (pt) 1999-07-13
CA2237189C (en) 2002-09-03
CA2237189A1 (en) 1997-07-17

Similar Documents

Publication Publication Date Title
DE69722940D1 (en) Intravaskuläre prothese
DE69634986D1 (en) Modulares wandlersystem
DE59704951D1 (en) Plättchenförmiges titandioxidpigment
DE69715838D1 (en) Thermomorphe drucksensitive klebmittel
DE69608577D1 (en) Thermostabiler schalldämmstoff
DE69711882D1 (en) Carbolinderivate
DE69702926D1 (en) Polyurethanhartschäume
DE69705420D1 (en) Polyurethanhartschäume
DE69708059D1 (en) Thiophenopyrimidine
DE69718335D1 (en) Sms-alarm
DE59705192D1 (en) Lcp-blends
DE69719214D1 (en) Diamantfilmdepositionsmethode
DE59711450D1 (en) Arylalkanoylpyridazine
DE69621466D1 (en) Thermoplastische hydroxy-phenoxyetherpolymerverbundwerkstoffe
DE69703480D1 (en) Anionische photokatalysator
DE59700372D1 (en) Blockcopolymere
GB9714129D0 (en) Azetidines
DE69719544D1 (en) Pyrazolderivate
ZA9747B (en) Azetidines
DE69720038D1 (en) Aminopyrazolderivate
DE69710573D1 (en) Morpholinyl-anthracyclinderivate
DE59707730D1 (en) Peripheralpumpe
DE59703905D1 (en) Linearmotorgetriebene transportanlage
DE59704086D1 (en) Twin-dualmode-filter
AU131131S (en) Handleset

Legal Events

Date Code Title Description
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20021220

Year of fee payment: 7

ODBC Application rejected